DJ ImmunoCellular Files 8K - Director, Officer or Compensation Filing >IMUC
ImmunoCellular Therapeutics Ltd. (IMUC) filed a Form 8K - Director, Officer or Compensation Filing - with the U.S Securities and Exchange Commission on October 10, 2018.
In connection with the Company's intention to delist its Common Stock and Listed Common Stock Warrants, on October 10, 2018, Dr. Anthony Gringeri notified the Company that he resigned from the Board and as President and Chief Executive Officer of the Company, effective as of October 15, 2018. On the same date, David Fractor and Dr. Steven Swanson each notified the Company of his resignation as Chief Financial Officer and Senior Vice President, as applicable, in each case as of October 15, 2018.
This Current Report on Form 8-K contains certain forward-looking statements, including statements regarding the Company's intentions and current expectations concerning, among other things, statements regarding the Company's ability to delist its Common Stock and Listed Common Stock Warrants from the NYSE American and deregister its Common Stock and Listed Common Stock Warrants under the Exchange Act, the continuation of Dr. Gringeri, Mr. Fractor and Dr. Swanson as consultants to the Company and the Company's ability to enter into and complete any strategic sale of its assets. Forward-looking statements are not guarantees of future performance and are subject to a number of risks and uncertainties, including the availability of resources to continue to develop the Company's product candidates and the uncertain timing of completion and success of clinical trials. Additional risks and uncertainties are described under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q for the period ended June 30, 2018 and subsequent filings with the SEC. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/822411/000119312518299252/d638594d8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/822411/000119312518299252/0001193125-18-299252-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.
(END) Dow Jones Newswires
October 15, 2018 16:35 ET (20:35 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.